# A Phase I Study of HW201877 in Healthy Subjects

> **NCT07373457** · PHASE1 · RECRUITING · sponsor: **Wuhan Humanwell Innovative Drug Research and Development Center Limited Company** · enrollment: 104 (estimated)

## Conditions studied

- Healthy Participants
- IBD (Inflammatory Bowel Disease)

## Interventions

- **DRUG:** HW201877 capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07373457
- **Lead sponsor:** Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07373457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07373457, "A Phase I Study of HW201877 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07373457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*